- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01494441
Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease
A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:
- instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score > 30.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
- Requires fusion of a single level disc space from L1 to S1.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
- Had previous spinal fusion surgical procedure at the involved level.
- Require spinal fusion at more than one lumbar level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
- Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy.
- Has overt or active bacterial infection, either local or systemic.
- Is grossly obese, i.e., weight > 40% over ideal for their age and height.
- Has fever ( temperature >101°F oral) at the time of surgery.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Is a tobacco user at the time of surgery.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
- Has received any previous exposure to any/all BMPs of either human or animal extraction.
- Has a history of severe allergy (anaphylaxis).
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rhBMP-2/BCP
|
The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Other Names:
|
Experimental: rhBMP-2/BCP/TSRH® Spinal System
|
rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
Other Names:
|
Active Comparator: Autograft/TSRH® Spinal System
|
The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fusion
Time Frame: 24 month
|
Fusion is defined as:
|
24 month
|
Pain/Disability Status
Time Frame: 24 month
|
The self-administered Oswestry Low Back pain Disability Questionnaire will be used.
Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
|
24 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General Health Status (SF-36)
Time Frame: 24 month
|
24 month
|
|
Patient Satisfaction
Time Frame: 24 month
|
24 month
|
|
Patient Global Perceived Effect
Time Frame: 24 month
|
24 month
|
|
Hip (Donor Site) Pain
Time Frame: 24 month
|
24 month
|
|
Pain Status (back pain, leg pain)
Time Frame: 24 month
|
24 month
|
|
Neurological Status Success
Time Frame: 24 month
|
Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale.
Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.
|
24 month
|
Overall Success
Time Frame: 24 month
|
24 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-9805
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
ReGelTec, Inc.Not yet recruitingDegenerative Disc Disease (DDD)
Clinical Trials on rhBMP-2/BCP
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsCompleted
-
University of BaghdadRecruitingHypertension | Diabetes Mellitus | Blood DiseaseIraq
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Xijing HospitalNot yet recruitingOsteoporosis | Spinal Fusion
-
University of Alabama at BirminghamNot yet recruitingBone LossUnited States
-
Virginia Spine InstituteCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedFracturesAustralia, United States, Finland, Canada, France, Germany, United Kingdom, Hungary, Norway, Sweden
-
Lindenhofgruppe AGRecruitingDegenerative Disc Disease | Spondylosis | SpondylolisthesisSwitzerland
-
Universidad Complutense de MadridNORICUM SLRecruitingEdentulous Alveolar Ridge | Alveolar Bone Loss | Loss of Teeth Due to ExtractionSpain